PURPOSE: The 2000 National Institutes of Health Consensus Conference on Adjuvant Therapy of Breast Cancer recommended chemotherapy for all women with invasive cancer greater than 1 centimeter. Studies of long-term breast cancer survivors have found poorer quality of life (QOL) in women who received adjuvant chemotherapy. The aim of this article is to characterize physical and psychosocial recovery as a function of chemotherapy receipt in the year after medical treatment completion. PATIENTS AND METHODS: Prospective longitudinal survey data (RAND SF-36 and Breast Cancer Prevention Trial [BCPT] Symptom Scales) collected from 558 women with breast cancer enrolled on the Moving Beyond Cancer (MBC) psychoeducational intervention trial were compared according to receipt of chemotherapy. MBC study enrollment occurred within 4 weeks after the end of primary treatment (eg, surgery, chemotherapy, radiation). Self-report questionnaire data collected at enrollment and at 2, 6, and 12 months thereafter were examined, controlling for intervention and with propensity score adjustment for imbalance of covariates. Outcome analyses were carried out by fitting linear mixed models by using SAS PROC MIXED. RESULTS:Longitudinal SF-36 scale scores did not differ by chemotherapy treatment exposure, and both groups improved significantly (P < .01) in the year after primary treatment ended. However, adjuvant chemotherapy treatment was associated with significantly more severe physical symptoms, including musculoskeletal pain (P = .01), vaginal problems (P < .01), weight problems (P = .01), and nausea (P = .03). CONCLUSION:Physical and psychosocial functioning improved significantly after breast cancer treatment, independent of receipt of adjuvant chemotherapy. Women who received chemotherapy experienced more severe and persistent physical symptoms that should be more effectively managed as part of survivorship care.
RCT Entities:
PURPOSE: The 2000 National Institutes of Health Consensus Conference on Adjuvant Therapy of Breast Cancer recommended chemotherapy for all women with invasive cancer greater than 1 centimeter. Studies of long-term breast cancer survivors have found poorer quality of life (QOL) in women who received adjuvant chemotherapy. The aim of this article is to characterize physical and psychosocial recovery as a function of chemotherapy receipt in the year after medical treatment completion. PATIENTS AND METHODS: Prospective longitudinal survey data (RAND SF-36 and Breast Cancer Prevention Trial [BCPT] Symptom Scales) collected from 558 women with breast cancer enrolled on the Moving Beyond Cancer (MBC) psychoeducational intervention trial were compared according to receipt of chemotherapy. MBC study enrollment occurred within 4 weeks after the end of primary treatment (eg, surgery, chemotherapy, radiation). Self-report questionnaire data collected at enrollment and at 2, 6, and 12 months thereafter were examined, controlling for intervention and with propensity score adjustment for imbalance of covariates. Outcome analyses were carried out by fitting linear mixed models by using SAS PROC MIXED. RESULTS: Longitudinal SF-36 scale scores did not differ by chemotherapy treatment exposure, and both groups improved significantly (P < .01) in the year after primary treatment ended. However, adjuvant chemotherapy treatment was associated with significantly more severe physical symptoms, including musculoskeletal pain (P = .01), vaginal problems (P < .01), weight problems (P = .01), and nausea (P = .03). CONCLUSION: Physical and psychosocial functioning improved significantly after breast cancer treatment, independent of receipt of adjuvant chemotherapy. Women who received chemotherapy experienced more severe and persistent physical symptoms that should be more effectively managed as part of survivorship care.
Authors: Patricia A Ganz; Lorna Kwan; Annette L Stanton; Janice L Krupnick; Julia H Rowland; Beth E Meyerowitz; Julienne E Bower; Thomas R Belin Journal: J Natl Cancer Inst Date: 2004-03-03 Impact factor: 13.506
Authors: Patricia A Ganz; Gail A Greendale; Laura Petersen; Barbara Kahn; Julienne E Bower Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Emily E Ventura; Patricia A Ganz; Julienne E Bower; Liana Abascal; Laura Petersen; Annette L Stanton; Catherine M Crespi Journal: Breast Cancer Res Treat Date: 2013-11-01 Impact factor: 4.872
Authors: Heather M Derry; Lisa M Jaremka; Jeanette M Bennett; Juan Peng; Rebecca Andridge; Charles Shapiro; William B Malarkey; Charles F Emery; Rachel Layman; Ewa Mrozek; Ronald Glaser; Janice K Kiecolt-Glaser Journal: Psychooncology Date: 2014-10-21 Impact factor: 3.894
Authors: Jesus G Ulloa; Marian Hemmelgarn; Lori Viveros; Patience Odele; Nancy R Feldman; Patricia A Ganz; Melinda Maggard-Gibbons Journal: Surgery Date: 2015-05-29 Impact factor: 3.982
Authors: Patricia A Ganz; Lorna Kwan; Steven A Castellon; Amy Oppenheim; Julienne E Bower; Daniel H S Silverman; Steve W Cole; Michael R Irwin; Sonia Ancoli-Israel; Thomas R Belin Journal: J Natl Cancer Inst Date: 2013-04-19 Impact factor: 13.506
Authors: Sine Rossen; Karen Trier; Berit Christensen; Martina A Eriksen; Ann-Dorthe Zwisler; Jette Vibe-Petersen Journal: Support Care Cancer Date: 2019-08-02 Impact factor: 3.603
Authors: Joanne S Buzaglo; Suzanne M Miller; Jeffery Kendall; Annette L Stanton; Kuang-Yi Wen; John Scarpato; Fang Zhu; Jennifer Lyle; Julia Rowland Journal: J Cancer Surviv Date: 2012-12-11 Impact factor: 4.442
Authors: Catherine Marinac; Ruth E Patterson; Adriana Villasenor; Shirley W Flatt; John P Pierce Journal: J Cancer Surviv Date: 2014-02-26 Impact factor: 4.442